DexCom Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $112.62
- Today's High:
- $115
- Open Price:
- $114.27
- 52W Low:
- $66.8925
- 52W High:
- $134.765
- Prev. Close:
- $113.96
- Volume:
- 1471712
Company Statistics
- Market Cap.:
- $44.04 billion
- Book Value:
- 5.519
- Revenue TTM:
- $2.91 billion
- Operating Margin TTM:
- 13.44%
- Gross Profit TTM:
- $1.88 billion
- Profit Margin:
- 11.73%
- Return on Assets TTM:
- 4.74%
- Return on Equity TTM:
- 16.35%
Company Profile
DexCom Inc had its IPO on 2005-04-14 under the ticker symbol DXCM.
The company operates in the Healthcare sector and Medical Devices industry. DexCom Inc has a staff strength of 7,500 employees.
Stock update
Shares of DexCom Inc opened at $114.27 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $112.62 - $115, and closed at $114.4.
This is a +0.39% increase from the previous day's closing price.
A total volume of 1,471,712 shares were traded at the close of the day’s session.
In the last one week, shares of DexCom Inc have slipped by -0.52%.
DexCom Inc's Key Ratios
DexCom Inc has a market cap of $44.04 billion, indicating a price to book ratio of 24.6553 and a price to sales ratio of 16.5357.
In the last 12-months DexCom Inc’s revenue was $2.91 billion with a gross profit of $1.88 billion and an EBITDA of $530.70 million. The EBITDA ratio measures DexCom Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, DexCom Inc’s operating margin was 13.44% while its return on assets stood at 4.74% with a return of equity of 16.35%.
In Q4, DexCom Inc’s quarterly earnings growth was a positive 16.6% while revenue growth was a positive 16.8%.
DexCom Inc’s PE and PEG Ratio
- Forward PE
- 120.4819
- Trailing PE
- 140.6914
- PEG
- 11.3373
Its diluted EPS in the last 12-months stands at $0.81 per share while it has a forward price to earnings multiple of 120.4819 and a PEG multiple of 11.3373. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into DexCom Inc’s profitability.
DexCom Inc stock is trading at a EV to sales ratio of 16.0212 and a EV to EBITDA ratio of 103.1204. Its price to sales ratio in the trailing 12-months stood at 16.5357.
DexCom Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.39 billion
- Total Liabilities
- $1.84 billion
- Operating Cash Flow
- $-194100000.00
- Capital Expenditure
- $63.50 million
- Dividend Payout Ratio
- 0%
DexCom Inc ended 2023 with $5.39 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $5.39 billion while shareholder equity stood at $2.13 billion.
DexCom Inc ended 2023 with $0 in deferred long-term liabilities, $1.84 billion in other current liabilities, 400000.00 in common stock, $479.90 million in retained earnings and $25.70 million in goodwill. Its cash balance stood at $642.30 million and cash and short-term investments were $2.46 billion. The company’s total short-term debt was $793,100,000 while long-term debt stood at $1.20 billion.
DexCom Inc’s total current assets stands at $3.67 billion while long-term investments were $0 and short-term investments were $1.81 billion. Its net receivables were $713.30 million compared to accounts payable of $1.04 billion and inventory worth $306.70 million.
In 2023, DexCom Inc's operating cash flow was $-194100000.00 while its capital expenditure stood at $63.50 million.
Comparatively, DexCom Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $114.4
- 52-Week High
- $134.765
- 52-Week Low
- $66.8925
- Analyst Target Price
- $132.74
DexCom Inc stock is currently trading at $114.4 per share. It touched a 52-week high of $134.765 and a 52-week low of $134.765. Analysts tracking the stock have a 12-month average target price of $132.74.
Its 50-day moving average was $112.17 and 200-day moving average was $100.18 The short ratio stood at 4.86 indicating a short percent outstanding of 0%.
Around 42.3% of the company’s stock are held by insiders while 10084.7% are held by institutions.
Frequently Asked Questions About DexCom Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.